Skip to main content
Clinical Trials/NCT05495945
NCT05495945
Completed
Phase 2

Ultrasonic Deep Brain Stimulation During Anesthetic Sedation

University of Michigan1 site in 1 country13 target enrollmentAugust 26, 2022
ConditionsMental Function

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Mental Function
Sponsor
University of Michigan
Enrollment
13
Locations
1
Primary Endpoint
Blood Oxygen Level Dependent (BOLD) Response to Visual Stimuli
Status
Completed
Last Updated
last year

Overview

Brief Summary

The purpose of this study is to see if mental functions take place during different levels of anesthesia. The researchers expect to gain a deeper understanding of mental function during different levels of anesthesia, and to evaluate if the use of ultrasonic brain stimulation accelerates return to consciousness.

Detailed Description

The decision was made in 2023 to focus on the Central Thalmus arm only for this trial. Participants were only randomized to this arm.

Registry
clinicaltrials.gov
Start Date
August 26, 2022
End Date
October 7, 2023
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Zirui Huang

Research Assistant Professor, Anesthesiology and Research Fellow

University of Michigan

Eligibility Criteria

Inclusion Criteria

  • The participants will be right-handed adults
  • Body mass index (BMI) less than
  • All subjects will be English speakers.

Exclusion Criteria

  • Participants will be excluded if they have any medical contraindication to MRI scanning
  • Unable to undergo MRI scanning because of possible pregnancy or currently breastfeeding,
  • Metallic substances in the body, claustrophobia, anxiety, or cardiopulmonary disease;
  • Intracranial structural abnormality on T1-weighted MRI scans.
  • Potential subjects will be excluded if they have a history of allergy to propofol, eggs or egg products, soybean or soybean products,
  • Neurological, cardiovascular, or pulmonary illness;
  • Head injury with loss of consciousness;
  • Learning disability or other developmental disorder; sleep apnea or any severe snoring history;
  • Gastroesophageal reflux disease (GERD) or heartburn;
  • Pancreatitis or a history of pancreatitis, or sensory/motor loss sufficient to interfere with performance of the study. Participants with tattoos in the head or neck region will be excluded from study; other tattoos are subject to determination by investigators based on their assessment regarding participant safety. To eliminate aspiration risk subjects will also be excluded if they have had recent food or liquid intake (within 8 hours). Subjects will be excluded if they have a history of drug use, have a positive drug screen, are unwilling to abstain from alcohol for 24 hours prior to dosing, or have a current history of nicotine use. Women will be required to take a pregnancy test prior to participation to ensure a negative result. The pre-scan drug screen and pregnancy test will be paid for by the study.

Outcomes

Primary Outcomes

Blood Oxygen Level Dependent (BOLD) Response to Visual Stimuli

Time Frame: Up to 90 minutes

BOLD signal was measured by Magnetic Resonance Imaging (MRI) scanning of the brain in response to a visual stimuli. This method reflected changes in oxygenation of blood in the brain during a scene-processing task.

Secondary Outcomes

  • Perceptual Criterion Derived From the Signal Detection Theory (SDT)(Up to 90 minutes)
  • Grip Force(Up to 90 minutes)
  • Sensitivity Derived From the Signal Detection Theory (SDT)(Up to 90 minutes)

Study Sites (1)

Loading locations...

Similar Trials